Our Educational Projects – 2022
The following projects are currently ongoing and will be developed by SPCC on a long-term basis.
Adverse Events Management and Interstitial Lung Disease (ILD) Detection Project
Supported by AstraZeneca and Daiichi Sankyo
Interstitial lung disease (ILD) is an issue in many cancers and cancer treatments.
This multi-step project will consist of: 1) an online Task Force; 2) a Scientific Position Statement; 3) five Podcasts; 4) a series of Educational Webinars; 5) a Virtual Event.
Artificial Intelligence in Cancer Care Educational Project
Supported by AstraZeneca, Novartis and Roche
Artificial intelligence has given rise to great expectations for improving cancer diagnosis, prognosis and therapy but has also highlighted some of its inherent outstanding challenges, such as potential implicit biases in training datasets, data heterogeneity and the scarcity of external validation cohorts.
SPCC will carry out a project to develop knowledge and competences on integration of AI in Cancer Care Continuum: from diagnosis to clinical decision-making.
Cancer & Covid: Prevention and Treatment including Monoclonal Antibodies (MoABs)
Supported by AstraZeneca
The outbreak of the Coronavirus disease 2019 (COVID-19) pandemic has caused worldwide problems in the care of cancer patients. In particular, the therapy of cancer patients, both outpatient and inpatient, has been substantially impacted by major restrictions due to the isolation and hygiene measures.
The aim of this project is to spread awareness and knowledge among HCPs on what is currently available to protect at-risk patients, prevent more serious damage due to COVID-19 disease and improve patients' quality of life in a COVID-19 risk or infection setting.
Telemedicine Project Phase 2 – 2022: the Implementation and Integration of Telemedicine in the Cancer Care Continuum
Supported by AstraZeneca, Eisai and Pfizer
Telemedicine promises to revolutionize care pathways for cancer patients as modern health systems design and conceptualize new ways to manage the entire Cancer Care Continuum, moving from hospital-centered models of care to patient-centered, proximity-based approaches. The fundamental concept is that information and data move, not patients.